Abstracts tagged "pain"

Abstract Number: 1064 • ACR Convergence 2024
Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
Shannon Herndon¹, Jack Kimball¹ and David Leverenz², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Palliative medicine prioritizes quality of life and relief of suffering in serious illness. Despite high morbidity and mortality in rheumatic disease, data suggests that…
Abstract Number: 1215 • ACR Convergence 2024
Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Maria Intriago¹, Puran Nepal², Laura L. Daniel¹, Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Adriana M. Hung⁴ and Cecilia P. Chung¹, ¹University of Miami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
Abstract Number: 1474 • ACR Convergence 2024
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Christopher Ritchlin¹, Ennio Lubrano², Maria Sole Chimenti³, Evan Leibowitz⁴, Mohamed Sharaf⁵, Oyediran Adelakun⁶, Emmanouil Rampakakis⁷, Francois Nantel⁸, Frederic Lavie⁹ and Atul Deodhar¹⁰, ¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ³Rheumatology, Allergology and Clinical Immunology, System Medicine Department, University of Rome Tor Vergata, Rome, Italy, ⁴Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶Janssen Research & Development, LLC, Titusville, NJ, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Nantel Medsci Consult, Montreal, QC, Canada, ⁹Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In previous DISCOVER (D)1 and 2 analyses, the fully human IL-23p19-subunit inhibitor guselkumab (GUS) was associated with robust and sustained improvement in PsA signs/symptoms…
Abstract Number: 2101 • ACR Convergence 2024
Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis
Hannah Brubeck¹, David Azizi², Sarah Wetzel², Marianna Olave², Rachel Gillcrist³, Bridget Kramer⁴, Bibiana Ateh⁵, Daniel White⁶, Carla Scanzello⁷, Tuhina Neogi⁸, Alexis Ogdie⁹, Bryant England⁴, Mercedes Quinones¹⁰, Katherine Wysham¹¹ and Joshua Baker⁷, ¹VA Puget Sound Health Care System, Seattle, WA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Washington DC VA Medical Center, Washington, DC, ⁶University of Delaware, Newark, DE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰Washington DC VA Medical Center, Bethesda, MD, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Despite strong recommendations for physical activity in knee osteoarthritis (KOA) clinical practice guidelines, only a small fraction of those with KOA meet guidelines for…
Abstract Number: PP06 • ACR Convergence 2024
Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Since receiving my rheumatoid arthritis (RA) diagnosis in 2015, I have found that one of my top five strategies to manage my symptoms is spending…
Abstract Number: 0480 • ACR Convergence 2024
Can’t Sleep, Won’t Sleep: A Systematic Review and Meta-Analysis of Insomnia Prevalence in 70,105 Rheumatoid Arthritis Patients
Mohamed Abdelsalam¹, Mamdouh Ahmed Khairy², Mohamed Reda Awad³, Aly Alnabawy², Maryam Taha⁴ and Mohamed Al-Adl Ali Ali², ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Al-Azhar university Cairo branch, Cairo, Egypt, ³Al Azhar University, Cairo, Egypt, Giza, Egypt, ⁴Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt
Background/Purpose: Insomnia is a significant challenge for rheumatoid arthritis (RA) patients. Chronic pain conditions often exacerbate sleep disturbances, creating a vicious cycle where pain and…
Abstract Number: 1174 • ACR Convergence 2024
Effects of Electroacupuncture on Pain and Joint Deformity in Rat Models of Knee Osteoarthritis: A Study on the Differences in Acupoints Used
Hideshi Ikemoto, Oyunchimeg Chuluunbat, Takayuki Okumo, Naoki Adachi, Tadashi Hisamitsu and Masataka Sunagawa, Showa university, Shinagawa-ku, Tokyo, Japan
Background/Purpose: ADAMTS5, a member of the ADAMTS enzyme family, is a key enzyme in the degradation of cartilage in the early stages of knee osteoarthritis…
Abstract Number: 1216 • ACR Convergence 2024
Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions
Larry Moreland¹, Rowe Brookfield² and Adam Laitman², ¹University of Colorado, Denver, CO, ²Salix Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In patients taking opioid analgesics, opioid-induced constipation (OIC) is estimated to affect between 41% to 80% of patients and is caused by peripheral mu-opioid…
Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Jennifer Rogers¹, Megan Clowse², David Pisetsky³, Jayanth Doss⁴, Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Rebecca Sadun⁴, Kai Sun⁴ and Amanda Eudy⁶, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…
Abstract Number: 2104 • ACR Convergence 2024
The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review
Sylvain Mathieu¹, Liisa Kuhi², Philip G Conaghan³, Niels Eijkelkamp⁴, Yves Henrotin⁵, Eva Kosek⁶, Hans-George Schaible⁷, Ali Mobasheri⁸, Kalle Kisand⁹ and Jérémie Sellam¹⁰, and GO-PAIN working group, ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²East Tallinn Central Hospital, Tallinn, Estonia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴University Medical Center, Umtrecht, Netherlands, ⁵MusculoSkeletal Innovative research Lab (mSKIL), Liege, Belgium, ⁶Karolinska Institute, Stockholm, Sweden, ⁷Institute of Physiology, Jena, Germany, ⁸Research Unit of Medical Imaging, Physics and Technology, Ouli, Finland, ⁹University of Tartu, Tartu, Estonia, ¹⁰Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Chronic joint pain is a major factor driving poor quality of life in people with osteoarthritis (OA). A better understanding of the complex mechanisms…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
Abstract Number: 0518 • ACR Convergence 2024
Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis
Rieke Alten¹, Bruno Fautrel², Philip G Conaghan³, Dick de Vries⁴, Margaux Faes⁵, Mercedes Piovesan⁶, Katrien Van Beneden⁷, Chris Watson⁸, Angelique E.A.M. Weel-Koenders⁹, Eugen Feist¹⁰ and Kurt de Vlam¹¹, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Clinical Development, Galapagos BV, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Medical Affairs, Galapagos Biopharma Spain SLU, Madrid, Spain, ⁷Medical Affairs, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁹Erasmus School of Health Policy and Management, Erasmus University Rotterdam, and Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands, ¹⁰Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, ¹¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: Quality of life for patients with RA can be severely impacted by pain, fatigue and impaired physical functioning.1 Filgotinib (FIL) has demonstrated early onset…
Abstract Number: 1178 • ACR Convergence 2024
Can Immersive Virtual Reality Improve the Effect of Meditation for People with Fibromyalgia?
Nancy Baker¹, Aliza Spielman¹ and Robert Edwards², ¹Tufts University, Medford, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a common and disabling condition characterized by widespread muscular pain. Meditation has been shown to alleviate affective pain in people with…
Abstract Number: 1217 • ACR Convergence 2024
Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California
Maggie Hui¹, Nicholas Jackson², Angela Pham¹, Keren Chen², David Elashoff², ziva Cooper³ and Veena Ranganath⁴, ¹David Geffen School of Medicine at UCLA, Los Angeles, ²UCLA Department of Medicine Statistics Core, Los Angeles, ³UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles, ⁴UCLA, Los Angeles, CA
Background/Purpose: Approximately 12-20% of Rheumatology patients use cannabis (Fitzcharles 2020, Wipfler 2022, Rampakakis 2023). Despite the legalization of medical cannabis in California more than 2…
Abstract Number: 1657 • ACR Convergence 2024
Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis
Marie Binvignat¹, Maria Marco-Salvador¹, Johanna Dubois¹, Paul Stys¹, Alice Courties², Fabien Pitoiset¹, Alexandra Roux³, Michele Barbier⁴, Roberta Lorenzon², Signe Hassler³, Claire Ribet¹, helene Vantomme¹, Leslie Adda¹, Vanessa Mhanna¹, Nicolas Coatnoan², Gwladys Fourcade¹, Vimala Didelot¹, PIerre Barennes¹, Lise Minssen², Caroline Aheng¹, Sanchita Bhattacharya⁵, Yannick Marie⁶, Atul J. butte⁵, Adrien Six¹, Nicolas Tchitcheck¹, Michelle Rosenzwajg¹, Francis Berenbaum¹, David Klatzmann¹, Encarnita Mariotti-Ferrandiz¹ and Jérémie Sellam⁷, ¹Sorbonne University, Paris, France, ²AP-HP, Paris, France, ³Sorbonne University, Paris, ⁴AP-HP, Paris, ⁵UCSF, San Francisco, ⁶ICM, Paris, France, ⁷Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France
Background/Purpose: Pain is the main osteoarthritis (OA) symptom and remains poorly understood. While significant attention has been given to the potential role of innate immunity,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].